APT 102
Alternative Names: APT-102; AZD-3366Latest Information Update: 28 Sep 2024
At a glance
- Originator APT Therapeutics
- Developer APT Therapeutics; AstraZeneca
- Class Anti-inflammatories; Anti-ischaemics; Antiplatelets; Antithrombotics; Cardiovascular therapies; Enzymes; Recombinant proteins; Vascular disorder therapies
- Mechanism of Action Apyrase replacements; Platelet activating factor inhibitors; Platelet aggregation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Myocardial infarction; Stroke; Thrombosis
- Discontinued Cardiovascular disorders
Most Recent Events
- 28 Sep 2024 No recent reports of development identified for preclinical development in Myocardial-infarction in United Kingdom (IV)
- 31 Jul 2023 Discontinued - Phase-I for Cardiovascular disorders (In volunteers, In adults) in USA (IV) before July 2023 (AstraZeneca pipeline, July 2023)
- 05 Nov 2022 Pharmacokinetics, pharmacodynamics and adverse events data from a phase I trial presented at the American Heart Association Scientific Sessions 2022 (AHA-2022)